A University of Alberta research team has developed a more effective way to deliver topical pain relief for chronic conditions like arthritis.
Topical non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac have traditionally been compounded by pharmacists in creams or gels using five, 10 or an even higher percentage of the active ingredient.
The new product, FoamaDerm®, is a microemulsion foam that has been shown to provide pain relief at just two per cent strength.







